DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Stintzing S, Jung L, Rossius DP. et al.
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
J Clin Oncol 2014
32. Suppl 03; abstract 445

Download Bibliographical Data

Access: